• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Practical, legal, and ethical issues in expanded access to investigational drugs.

作者信息

Darrow Jonathan J, Sarpatwari Ameet, Avorn Jerry, Kesselheim Aaron S

出版信息

N Engl J Med. 2015 Jan 15;372(3):279-86. doi: 10.1056/NEJMhle1409465.

DOI:10.1056/NEJMhle1409465
PMID:25587952
Abstract
摘要

相似文献

1
Practical, legal, and ethical issues in expanded access to investigational drugs.扩大试验性药物可及性中的实践、法律及伦理问题。
N Engl J Med. 2015 Jan 15;372(3):279-86. doi: 10.1056/NEJMhle1409465.
2
Access before approval--a right to take experimental drugs?批准前获取——有权使用实验性药物？
N Engl J Med. 2006 Aug 3;355(5):437-40. doi: 10.1056/NEJMp068132.
3
FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.美国食品药品监督管理局扩大治疗用研究性药物可及性的拟议法规：打着改革幌子的现状。
Food Drug Law J. 2009;64(1):183-223.
4
Expanded access to investigational drugs.
N Engl J Med. 2015 Apr 9;372(15):1473-4. doi: 10.1056/NEJMc1501823.
5
Expanded access to investigational drugs.
N Engl J Med. 2015 Apr 9;372(15):1473. doi: 10.1056/NEJMc1501823.
6
Shifting terrain in the regulation of off-label promotion of pharmaceuticals.药品未标示用途推广监管方面不断变化的形势。
N Engl J Med. 2009 Apr 9;360(15):1557-66. doi: 10.1056/NEJMhle0807695.
7
A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.一项徒劳无功的研究：阿比盖尔改善晚期药物可及性联盟不会扩大绝症患者对实验性药物的可及性。
Seton Hall Law Rev. 2009;39(2):559-603.
8
Food and Drug Administration Drug Approval Process: A History and Overview.食品药品监督管理局药品审批流程：历史与概述
Nurs Clin North Am. 2016 Mar;51(1):1-11. doi: 10.1016/j.cnur.2015.10.007. Epub 2016 Jan 13.
9
The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?美国食品药品监督管理局的早期准入和快速通道批准计划：它们的成效如何？
Food Drug Law J. 1995;50(4):503-31.
10
Expanding access to investigational drugs for treatment use: a policy analysis and legislative proposal.
Health Matrix Clevel. 2009 Winter;19(1):205-46.

引用本文的文献

1
Augmenting Treatment Arms With External Data Through Propensity-Score Weighted Power Priors: An Application in Expanded Access.通过倾向得分加权功率先验使用外部数据增强治疗组：在扩大准入中的应用
Stat Med. 2025 Aug;44(18-19):e70168. doi: 10.1002/sim.70168.
2
Ethical Issues in Pediatric Precision Oncology in Singapore.新加坡儿科精准肿瘤学中的伦理问题。
Asian Bioeth Rev. 2025 Mar 3;17(2):293-306. doi: 10.1007/s41649-024-00351-z. eCollection 2025 Apr.
3
Benefit assessment of extended dosing in cancer patients after their withdrawal from clinical trials.
癌症患者退出临床试验后延长给药的获益评估
Front Pharmacol. 2023 Dec 15;14:1178002. doi: 10.3389/fphar.2023.1178002. eCollection 2023.
4
Results from Expanded Access Programs: A Review of Academic Literature.拓展准入项目的结果：学术文献回顾。
Drugs. 2023 Jun;83(9):795-805. doi: 10.1007/s40265-023-01879-4. Epub 2023 May 18.
5
Early access provision: Awareness, educational needs and opportunities to improve oncology patients' access to care.早期准入规定：提高肿瘤患者就医机会的认知、教育需求及机遇
Front Oncol. 2022 Oct 26;12:714516. doi: 10.3389/fonc.2022.714516. eCollection 2022.
6
Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs.学术肿瘤学家对提供扩展获得研究性药物的看法。
JAMA Netw Open. 2022 Nov 1;5(11):e2239766. doi: 10.1001/jamanetworkopen.2022.39766.
7
A survey of pediatric hematologists/oncologists' perspectives on single patient Expanded Access and Right to Try.一项关于儿科血液科医生/肿瘤医生对单患者扩大使用及“尝试权”观点的调查。
Med Access Point Care. 2021 Apr 19;5:23992026211005991. doi: 10.1177/23992026211005991. eCollection 2021 Jan-Dec.
8
The 'false hope' argument in discussions on expanded access to investigational drugs: a critical assessment.讨论扩大试验性药物的获取途径时的“虚假希望”论点：批判性评估。
Med Health Care Philos. 2022 Dec;25(4):693-701. doi: 10.1007/s11019-022-10106-y. Epub 2022 Aug 11.
9
Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations.从罕见病药物扩大使用中获取证据：挑战与建议
Front Pharmacol. 2022 May 23;13:913567. doi: 10.3389/fphar.2022.913567. eCollection 2022.
10
Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.肿瘤学家对患者权利和获得同情用药的思考：来自学术癌症中心的定性访谈研究。
PLoS One. 2021 Dec 17;16(12):e0261478. doi: 10.1371/journal.pone.0261478. eCollection 2021.